These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

7782 related articles for article (PubMed ID: 2702982)

  • 1. Selectivity of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide towards Lewis lung carcinoma and human tumour cell lines in vitro.
    Finlay GJ; Baguley BC
    Eur J Cancer Clin Oncol; 1989 Feb; 25(2):271-7. PubMed ID: 2702982
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cell line selectivity and DNA breakage properties of the antitumour agent N-[2-(dimethylamino)ethyl]acridine-4-carboxamide: role of DNA topoisomerase II.
    Schneider E; Darkin SJ; Lawson PA; Ching LM; Ralph RK; Baguley BC
    Eur J Cancer Clin Oncol; 1988 Nov; 24(11):1783-90. PubMed ID: 2850193
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chemoprotection by 9-aminoacridine derivatives against the cytotoxicity of topoisomerase II-directed drugs.
    Finlay GJ; Wilson WR; Baguley BC
    Eur J Cancer Clin Oncol; 1989 Dec; 25(12):1695-701. PubMed ID: 2561099
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Unusual dynamics of killing of cultured Lewis lung cells by the DNA-intercalating antitumour agent N-[2-(dimethylamino)ethyl]acridine-4-carboxamide.
    Haldane A; Finlay GJ; Gavin JB; Baguley BC
    Cancer Chemother Pharmacol; 1992; 29(6):475-9. PubMed ID: 1568291
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro assessment of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide, a DNA-intercalating antitumour drug with reduced sensitivity to multidrug resistance.
    Finlay GJ; Marshall E; Matthews JH; Paull KD; Baguley BC
    Cancer Chemother Pharmacol; 1993; 31(5):401-6. PubMed ID: 8381721
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potentiation by phenylbisbenzimidazoles of cytotoxicity of anticancer drugs directed against topoisomerase II.
    Finlay GJ; Baguley BC
    Eur J Cancer; 1990; 26(5):586-9. PubMed ID: 1698074
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanism of cytotoxicity of N-[2-(dimethylamino)ethyl] acridine-4-carboxamide and of its 7-chloro derivative: the roles of topoisomerases I and II.
    Bridewell DJ; Finlay GJ; Baguley BC
    Cancer Chemother Pharmacol; 1999; 43(4):302-8. PubMed ID: 10071981
    [TBL] [Abstract][Full Text] [Related]  

  • 8. From amsacrine to DACA (N-[2-(dimethylamino)ethyl]acridine-4-carboxamide): selectivity for topoisomerases I and II among acridine derivatives.
    Finlay GJ; Riou JF; Baguley BC
    Eur J Cancer; 1996 Apr; 32A(4):708-14. PubMed ID: 8695277
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Divergent activity of derivatives of amsacrine (m-AMSA) towards Lewis lung carcinoma and P388 leukaemia in mice.
    Baguley BC; Kernohan AR; Wilson WR
    Eur J Cancer Clin Oncol; 1983 Nov; 19(11):1607-13. PubMed ID: 6688994
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of the action of the topoisomerase II poison amsacrine by simple aniline derivatives: evidence for drug-protein interactions.
    Finlay GJ; Atwell GJ; Baguley BC
    Oncol Res; 1999; 11(6):249-54. PubMed ID: 10691026
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Schedule dependence of activity of the amsacrine analogue CI-921 towards P388 leukaemia and Lewis lung carcinoma.
    Baguley BC; Grimwade CD; Kernohan AR
    Eur J Cancer Clin Oncol; 1985 Nov; 21(11):1337-41. PubMed ID: 3841068
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Carbamate analogues of amsacrine active against non-cycling cells: relative activity against topoisomerases IIalpha and beta.
    Turnbull RM; Meczes EL; Perenna Rogers M; Lock RB; Sullivan DM; Finlay GJ; Baguley BC; Austin CA
    Cancer Chemother Pharmacol; 1999; 44(4):275-82. PubMed ID: 10447574
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Topoisomerase I/II selectivity among derivatives of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide (DACA).
    Bridewell DJ; Finlay GJ; Baguley BC
    Anticancer Drug Des; 2001 Dec; 16(6):317-24. PubMed ID: 12375884
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of in vivo and in vitro drug sensitivities of Lewis lung carcinoma and P388 leukaemia to analogues of amsacrine.
    Baguley BC; Wilson WR
    Eur J Cancer Clin Oncol; 1987 Jun; 23(6):607-13. PubMed ID: 3653185
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetic toxicology of tricyclic carboxamides, a new class of DNA binding antitumour agent.
    Ferguson LR; Hill CM; Baguley BC
    Eur J Cancer; 1990; 26(6):709-14. PubMed ID: 2144158
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Experimental solid tumour activity of N-[2-(dimethylamino)ethyl]-acridine-4-carboxamide.
    Baguley BC; Zhuang L; Marshall E
    Cancer Chemother Pharmacol; 1995; 36(3):244-8. PubMed ID: 7781146
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of the cytotoxicity of amsacrine and its analogue CI-921 against cultured human and mouse bone marrow tumour cells.
    Ching LM; Finlay GJ; Joseph WR; Baguley BC
    Eur J Cancer; 1990 Jan; 26(1):49-54. PubMed ID: 2138478
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro and in vivo assessment of activity of new anilino-substituted analogues of amsacrine against Lewis lung carcinoma.
    Rewcastle GW; Denny WA; Wilson WR; Baguley BC
    Anticancer Drug Des; 1986 Nov; 1(3):215-22. PubMed ID: 3450294
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytokinetic differences in the action of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide as compared with that of amsacrine and doxorubicin.
    Haldane A; Holdaway KM; Finlay GJ; Baguley BC
    Cancer Chemother Pharmacol; 1993; 32(6):463-70. PubMed ID: 8258195
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A comparison of the effects of aphidicolin and other inhibitors on topoisomerase II-directed cytotoxic drugs.
    Haldane A; Finlay GJ; Baguley BC
    Oncol Res; 1993; 5(3):133-8. PubMed ID: 8260750
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 390.